Navigation Links
Hyperion Therapeutics Announces Enrollment of First Patient in Phase 1/2 Clinical Trial of GT4P in Patients With Urea Cycle Disorders
Date:10/23/2007

SOUTH SAN FRANCISCO, Calif., Oct. 23 /PRNewswire/ -- Hyperion Therapeutics, Inc. today announced that the first patient has been enrolled in a Phase 1/2 clinical trial of Glyceryl Tri (4-Phenylbutyrate) (GT4P) in patients with urea cycle disorders (UCDs).

(Logo: http://www.newscom.com/cgi-bin/prnh/20070905/AQW076LOGO)

"UCDs are complex disorders which require a multi-faceted management approach, including a protein restricted diet, amino acid supplementation, and pharmacological therapy," said Brendan Lee, M.D., Ph.D. the first investigator to enroll a patient in the GT4P Phase 1/2 trial and Professor, Department of Molecular and Human Genetics at Baylor College of Medicine. "We look forward to seeing the results from the clinical trials of GT4P in the management of UCDs."

The phase 1/2 study is designed to evaluate the safety, tolerability and ammonia scavenging effects of GT4P compared to BUPHENYL(R) (sodium phenylbutyrate) in patients with UCDs. A total of up to ten adults with stable UCD will be included in the trial, which is being conducted at US-based clinical sites. Estimated duration of treatment is 3 to 4 weeks.

"We are very excited about our research of GT4P focused on the chronic management of urea cycle disorders," said Marvin Garovoy, Senior Vice President of Clinical Development of Hyperion Therapeutics, Inc. "Initiation of this trial marks the beginning of several Hyperion clinical programs aimed at developing new therapies for hepatic disease."

About GT4P

GT4P is composed of a glycerol backbone covalently attached via ester linkages to three molecules of phenylbutyrate. It is a prodrug of BUPHENYL(R) (a currently FDA-approved adjunctive therapy in the chronic management of patients with urea cycle disorders involving deficiencies of carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), or argininosuccinic aci
'/>"/>

SOURCE Hyperion Therapeutics, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Cell Therapeutics, Inc. Management to Discuss Todays Announcement of Interim Pixantrone Study Results
2. Halozyme Therapeutics Enhanze Technology Large Protein Molecule Therapeutic Clinical Trial Results Presented at the 34th Annual Meeting of the Controlled Release Society
3. CV Therapeutics Identifies Potential Anti-Diabetic Mechanism of Action for Ranexa
4. GTC Biotherapeutics to Webcast Corporate Presentation at the C.E. Unterberg, Towbin Emerging Growth Life Opportunities Conference
5. Fat Kills Cancer: Turning Stem Cells from Fat Tissue into Personalized, Cancer-Targeted Therapeutics
6. A 4-Week Therapy with Transition Therapeutics E1-I.N.T. Leads to Sustained Reductions in Blood Glucose Levels for 6 Months Post-treatment in Type 2 Diabetes Patients
7. Clinical Trial Suggests Bone Marrow Stem Cells Are Useful for Spinal Cord Injury; PrimeCell Therapeutics Provided Pre-Clinical Study
8. Pieris Progresses Development of its Proprietary Biotherapeutics Platform: Successful Demonstration of Dual Targeting With Duocalin(R) Technology
9. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
10. Orexigen Therapeutics to Present Data on Contrave Impact on Visceral Fat and Insulin Resistance at American Diabetes Association 67th Scientific Sessions in Chicago June 23
11. Allos Therapeutics Reports Results for Phase 3 Enrich Study of Efaproxyn in Women With Brain Metastases Originating From Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/4/2015)... 04, 2015 Research ... addition of the "Pharmacovigilance (London, UK - ... Understanding PhV today - the principles ... in Drug safety. This course aims ... pharmacovigilance. New entrants as well as experienced operators ...
(Date:9/4/2015)... MENLO PARK, Calif. , Sept. 4, 2015 ... and the "Company"), a biopharmaceutical company focused on the ... its financial results for the fiscal year ending June ... highlights and expected near-term milestones. DelMar,s ... and live webcast for investors, analysts and other interested ...
(Date:9/3/2015)... YORK , Sept. 3, 2015 ... Your New Guide to that Market, its R&D and Sales ... to assess the future of cancer-treating medicines? Visiongain,s new report ... you stay ahead. There you discover financial data, R&D trends, ... In our analysis you see forecasted sales to ...
Breaking Medicine Technology:Pharmacovigilance Course: The Principles and Practice of Global PhV for those Working in Drug Safety (London, UK - December 7-9, 2015) 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 2DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 3DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 4DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 5DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 6DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 7DelMar Pharmaceuticals Reports Fiscal 2015 Year-End Financial Results and Provides Corporate Update 8World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 2World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 3World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 4World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 5World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 6World Cancer-Treating Drugs Industry and Market: Companies, Therapies, R&D and Forecasts 2015-2025 7
... at Self Regional Healthcare,s South Carolina Spine Center in ... of spinal conditions in its new advanced surgical operating ... Already recognized by leading health care ratings organization HealthGrades ... its commitment to advanced spinal care by becoming the ...
... YORK, Oct. 6 Pfizer (NYSE: ... its acquisition of FoldRx Pharmaceuticals, Inc., a privately held ... FoldRx Pharmaceuticals, Inc. is now a wholly owned subsidiary ... (Logo: http://www.newscom.com/cgi-bin/prnh/20100416/PFIZERLOGO) Pfizer Inc: ...
Cached Medicine Technology:Self Regional Healthcare Becomes First in the Southeast to Treat Spine Patients Using Advanced Integrated Operating Room Technology From Brainlab 2
(Date:9/5/2015)... ... September 05, 2015 , ... If you are nervous ... accidental needle sticks, there is a greater need than ever before for an idea ... SLIP GRIP SYRINGE to protect medical staff members and patients against accidental needle punctures. ...
(Date:9/4/2015)... ... 2015 , ... According to an article published September 1 by ... homes and assisted living facilities are receiving insufficient care that could actually be shortening ... was at one point close to death, not because of a medical condition, but ...
(Date:9/4/2015)... ... 04, 2015 , ... With TransCel from Pixel Film Studios users can simulate ... X. With TransCel users have full control over camera position and angle within 3D ... color, inner color, text, and more. With TransCel the possibilities are endless. , Users ...
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... IVF New ... host a New Hampshire fertility "ManchVegas Happy Hour" in Manchester for women who wish ... 15, 2015 at XO on Elm restaurant and lounge, 827 Elm Street, Manchester, NH ...
(Date:9/4/2015)... , ... September 04, 2015 , ... ... to benefit Core Compassion Project. Core Compassion Project is a non-profit organization ... to reduce the side effects of cancer treatments and recover their mobility, strength, ...
Breaking Medicine News(10 mins):Health News:Safety Feature for Needle Injections Invented by InventHelp Client (OCM-914) 2Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 2Health News:Op-Ed about Insufficient Care for Elderly Patients Highlights the Advantages of Quality, At-Home Care, says Dr. Michael Farzam 3Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:IVF New England to Host ManchVegas New Hampshire Fertility Happy Hour on October 15, 2015 in Manchester for Women Who Wish to Learn More About Fertility and Egg Freezing 2Health News:Girl’s Night Out to Benefit Core Compassion Project, Located at the Beautiful, Morning Glory Farm 2
... Ky., Oct. 15 Dave Robert,Armstrong, the nation,s fourth ... California, after a three month stay in,Louisville. Armstrong received ... by Kleinert, Kutz & Associates and University of,Louisville hand ... "I just want to thank the donor family," says ...
... A popular drug used to prevent blood,clotting during ... improve,outcomes for patients undergoing a life-saving surgical procedure. ... ep-ti-fy-bah-tide),- also increases the risk of bleeding. The ... University of Ottawa Heart Institute (UOHI),which sought to ...
... and driving home after a drink with a friend on 28 ... Villa was thrown through the windscreen, suffered massive head injuries and ... little sign of improvement. "He would open his eyes, but he ... Theresa Pape of the US Department of Veterans Affairs in Chicago, ...
... treatments for severely injured patients , , WEDNESDAY, Oct. ... cause movement in paralyzed limbs, researchers have found a ... use them to move a paralyzed wrist. , In ... a brain-computer interface to tap into brain cells, teach ...
... Thomson Reuters, the,world,s leading source of intelligent ... of Thomson Pharma KOLexperts, a,new solution designed to ... with key opinion leaders,(KOLs) and scientific experts. It ... allows users to rank life sciences KOLs with ...
... at ,Health and Pharma 2.0, session. , ... ... www.healthtalker.com , the word-of-mouth marketing (WOM) firm for the ... and CEO of HealthTalker, will be featured on the panel ...
Cached Medicine News:Health News:Fourth Hand Transplant Recipient Heads Home to California 2Health News:University of Ottawa Heart Institute Trial Finds Popular Blood Clotting Drug Does Not Improve Patient Outcomes and Increases Risk of Bleeding 2Health News:Patient roused from coma by a magnetic field 2Health News:Patient roused from coma by a magnetic field 3Health News:New Technique Activates Brain Neurons to Move Paralyzed Limb 2Health News:New Technique Activates Brain Neurons to Move Paralyzed Limb 3Health News:Thomson Reuters Launches Thomson Pharma KOLexperts(R) to Help the Pharmaceutical Industry Objectively Identify, Verify and Rank Scientific Experts, Product Advocates, Clinical Investigators and Key Opinion Leaders 2Health News:HealthTalker Founder and CEO Andrew Levitt to be Featured at 'Health 2.0: User-Generated Healthcare 2008' 2
Consensus Knee implants are designed to provide both joint and implant stability and allow near normal kinematics. The components are anatomic with porous and nonporous options. Six femoral/tibial an...
Scorpio CR Knee is designed to address normal knee kinematics, range of motion (ROM) and polyethylene wear....
... TC-PLUS Solution tricompartmental total knee prosthesis stems ... arthroplasty. State-of-the-art design and manufacturing technologies have ... biomechanical function as well as a favorable ... insert to keep wear to a minimum. ...
... Condylar Knee System has ... and refined with the ... graphics and manufacturing technology. ... implant stability, function, performance ...
Medicine Products: